Sarepta Therapeutics Inc, Cambridge MA, USA.
Broadstreet HEOR, Vancouver, BC, V6A 1A4 Canada.
J Neuromuscul Dis. 2022;9(4):477-492. doi: 10.3233/JND-210771.
BackgroundThe impact of age at autosomal recessive limb girdle muscular dystrophy (LGMDR) onset on progression to loss of ambulation (LOA) has not been well established, particularly by subtype.
To describe the characteristics of patients with adult-, late childhood-, and early childhood-onset LGMDR by subtype and characterize the frequency and timing of LOA.
A systematic review was conducted in MEDLINE, Embase and the Cochrane library. Frequency and timing of LOA in patients with LGMDR1, LGMDR2/Miyoshi myopathy (MM), LGMDR3-6, LGMDR9, and LGMDR12 were synthesized from published data.
In 195 studies, 695 (43.4%) patients had adult-, 532 (33.2%) had late childhood-, and 376 (23.5%) had early childhood-onset of disease across subtypes among those with a reported age at onset (n = 1,603); distribution of age at onset varied between subtypes. Among patients with LOA (n = 228), adult-onset disease was uncommon in LGMDR3-6 (14%) and frequent in LGMDR2/MM (42%); LGMDR3-6 cases with LOA primarily had early childhood-onset (74%). Mean (standard deviation [SD]) time to LOA varied between subtypes and was shortest for patients with early childhood-onset LGMDR9 (12.0 [4.9] years, n = 19) and LGMDR3-6 (12.3 [10.7], n = 56) and longest for those with late childhood-onset LGMDR2/MM (21.4 [11.5], n = 36).
This review illustrated that patients with early childhood-onset disease tend to have faster progression to LOA than those with late childhood- or adult-onset disease, particularly in LGMDR9. These findings provide a greater understanding of progression to LOA by LGMDR subtype, which may help inform clinical trial design and provide a basis for natural history studies.
常染色体隐性肢带型肌营养不良症(LGMD)发病年龄对丧失行走能力(LOA)的影响尚未得到充分证实,特别是按亚型划分时。
按亚型描述成年起病、晚发性儿童起病和早发性儿童起病的 LGMD 患者的特征,并描述 LOA 的发生频率和时间。
对 MEDLINE、Embase 和 Cochrane 图书馆进行系统检索。根据已发表的数据综合分析 LGMD1、LGMD2/肌间线蛋白病(MM)、LGMD3-6、LGMD9 和 LGMD12 患者的 LOA 发生率和时间。
在 195 项研究中,在有发病年龄报告的 1603 例患者中,695 例(43.4%)为成年起病,532 例(33.2%)为晚发性儿童起病,376 例(23.5%)为早发性儿童起病;各亚型的发病年龄分布不同。在有 LOA 的 228 例患者中,LGMD3-6 中成年起病不常见(14%),LGMD2/MM 中常见(42%);LGMD3-6 患者 LOA 主要发生在早发性儿童起病(74%)。不同亚型 LOA 的平均(标准差)发生时间不同,LGMD9 和 LGMD3-6 的早发性儿童起病患者 LOA 发生时间最短(12.0[4.9]岁,n=19;12.3[10.7]岁,n=56),LGMD2/MM 的晚发性儿童起病患者 LOA 发生时间最长(21.4[11.5]岁,n=36)。
本综述表明,早发性儿童起病的患者 LOA 进展速度快于晚发性儿童起病或成年起病的患者,LGMD9 尤其如此。这些发现对 LGMD 亚型的 LOA 进展情况有了更深入的了解,这可能有助于指导临床试验设计,并为自然史研究提供依据。